地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18771997407
邮箱:sales@amyjet.com

VWR作为全球领先的科学技术服务供应商,长期致力于在制药、生物技术、工业、教育、政府和医疗保健领域为实验室和量产客户提供优质产品、服务和解决方案。VWR has long been the leading global, independent provider of product and service solutions to laboratory and production customers, enabling science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries.
VWR的主要产品包括:
VWR Equipment and Instrumentation
All You Need for Analytical Chemistry
Centrifugation
Chemicals
Chromatography (R&D)
Cold Storage
Electrochemistry
Life Science
Liquid Handling
Microscopy
Ovens & Incubators
Organic Synthesis at VWR
Safety
Spectrophotometers
Temperature Measurement & Thermometers
Titration
Weighing
R&D Literature
Beckman Coulter
ELGA
Heidolph
Kimble
METTLER TOLEDO
Molecular Devices
Pall Laboratory
Panasonic Healthcare Corporation of North America
WHEATON
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="VWR"> VWR
Premetek公司致力于为学术客户和工业客户提供化学试剂、纳米材料和催化剂,同时也提供多领域的研发服务。通过不断地与业内专业企业进行技术整合,Premetek不断更新产品,并为材料科学和催化领域提供了最多样化和可扩展的选择。
Our retail objectives are to offer the most expansive selection of premium products, provide easy and friendly service, offer the fastest delivery time possible, and ensure that every customer is satisfied with their purchase. Our inventory is determined by extensive market research, attendance at international tradeshows and conferences, customer feedback, and working closely with industry experts and vendors. Premetek is committed to continually improving our services and being the premier online market place for all your needs.
Premetek公司的主要产品包括:
Nanomaterials
Nanomaterial Suspension
Pt,Pd Catalysts -Hydrogenation
Pt,Pd Catalysts -Red/Oxidation
Pt Catalysts - Electrochemistry
Pt Alloy Catalysts - Electrochemistry
Pd Alloy Catalysts - Electrochemistry
Pd,Ru,Ir,Rh,Au Catalysts - Electrochemistry
Fe,Co,Ni,Cu,Ag Catalysts - Electrochemistry
Pt,Pd,Ru,Ir,Rh,Au-Organometallics
Pt, Pd, Rh Homogeneous Catalysts
Custom Products
Special catalysts in stock
| 品名 | 货号 | 规格 |
| Aluminum titanate, Al2TiO5, 40 g each | N10A1000 | 40g |
| Barium strontium titanium oxide, BaSrTi2O6, 40 g each | N10B2000 | 40g |
| Calcium titanate, CaTiO3, 40 g each | N10C1000 | 40g |
| Calcium zirconium titanium oxide, CaZrTi2O3, 40 g each | N10C2000 | 40g |
| Cadmium tungsten oxide, CdWO4, 40 g each | N10C3000 | 40g |
| Cerium aluminate, CeAlO3, 40 g each | N10C4000 | 40g |
| Copper aluminate, CuAl2O4, 40 g each | N10C5000 | 40g |
| Iron nickel oxide, FeNiO4, 40 g each | N10I1000 | 40g |
| Lanthanum chromite, LaCrO3, 40 g each | N10L1000 | 40g |
| Lanthanum manganite , LaMnO3, 40 g each | N10L3000 | 40g |
| Lanthanum substituted lithium titanate, (LaLi3)TiO3, 40 g each | N10L5000 | 40g |
| Lead zirconium substituted titanate, PbZr0.2Ti0.8O3, 40 g each | N10L6000 | 40g |
| Manganese titanate, MnTiO3, 40 g each | N10M1000 | 40g |
| Magnesium aluminate, MgAl2O4, 40 g each | N10M2000 | 40g |
| Nickel cobalt oxide, NiCoO2, 40 g each | N10N1000 | 40g |
| Strontium bismuth niobium oxide, SrBi2Nb2O9, 50 g each | N10S1000 | 40g |
| Strontium ferrite, SrFe12O19, 40 g each | N10S2000 | 40g |
| Yttrium aluminum oxide, Y3Al5O12, 40 g each | N10Y1000 | 40g |
| Yttrium iron oxide, Y3Fe5O12, 40 g each | N10Y2000 | 40g |
| Zinc iron oxide, ZnFe2O4, 40 g each | N10Z1000 | 40g |
| Zinc titanium oxide, ZnTiO3, 40 g each | N10Z2000 | 40g |
| Concentrated Suspension of Nanoscaled Titanium Dioxide (TiO2), 5 kg | N-1000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2010 | 5kg |
| Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3000 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3010 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3020 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3130 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3220 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3230 | 5kg |
| 0.1% Pt on activated carbon powder, 10 g each | P10J1001 | 10g |
| 0.5% Pt on activated carbon powder, 10 g each | P10J1005 | 10g |
| 1.0% Pt on activated carbon powder, 10 g each | P10J1010 | 10g |
| 5.0% Pt on activated carbon powder, 10 g each | P10J1050 | 10g |
| 10% Pt on activated carbon powder, 10 g each | P10J1100 | 10g |
| 20% Pt on activated carbon powder, 10 g each | P10J1200 | 10g |
| 0.1% Pt on granular carbon, 10 g each | P10J2001 | 10g |
| 0.5% Pt on granular carbon, 10 g each | P10J2005 | 10g |
| 1.0% Pt on granular carbon, 10 g each | P10J2010 | 10g |
| 5.0% Pt on granular carbon, 10 g each | P10J2050 | 10g |
| 0.1% Pd on activated carbon powder, 10 g each | P30J1001 | 10g |
| 0.5% Pd on activated carbon powder, 10 g each | P30J1005 | 10g |
| 1.0% Pd on activated carbon powder, 10 g each | P30J1010 | 10g |
| 5.0% Pd on activated carbon powder, 10 g each | P30J1050 | 10g |
| 10% Pd on activated carbon powder, 10 g each | P30J1100 | 10g |
| 20% Pd on activated carbon powder, 10 g each | P30J1200 | 10g |
| 0.1% Pd on granular carbon, 10 g each | P30J2001 | 10g |
| 0.3% Pd on granular carbon, 10 g each | P30J2003 | 10g |
| 0.5% Pd on granular carbon, 10 g each | P30J2005 | 10g |
| 1.0% Pd on granular carbon, 10 g each | P30J2010 | 10g |
| 5.0% Pd on granular carbon, 10 g each | P30J2050 | 10g |
| 0.5% Pd on alumina spheres, 3 mm, SA= | P30L1005 | 10g |
| 1.0% Pd on alumina spheres, 3 mm, SA= | P30L1010 | 10g |
| 0.1% Pt on alumina powder, 10 g each | P10K1001 | 10g |
| 0.5% Pt on alumina powder, 10 g each | P10K1005 | 10g |
| 1.0% Pt on alumina powder, 10 g each | P10K1010 | 10g |
| 5.0% Pt on alumina powder, 10 g each | P10K1050 | 10g |
| 10% Pt on alumina powder, 10 g each | P10K1100 | 10g |
| 20% Pt on alumina powder, 10 g each | P10K1200 | 10g |
| 0.1% Pd on alumina powder, 10 g each | P30K1001 | 10g |
| 0.5% Pd on alumina powder, 10 g each | P30K1005 | 10g |
| 1.0% Pd on alumina powder, 10 g each | P30K1010 | 10g |
| 5.0% Pd on alumina powder, 10 g each | P30K1050 | 10g |
| 10% Pd on alumina powder, 10 g each | P30K1100 | 10g |
| 20% Pd on alumina powder, 10 g each | P30K1200 | 10g |
| 5% Pt on Vulcan XC-72 | P10A050 | 1g/5g |
| 10% Pt on Vulcan XC-72 | P10A100 | 1g/5g |
| 20% Pt on Vulcan XC-72 | P10A200 | 1g/5g |
| 30% Pt on Vulcan XC-72 | P10A300 | 1g/5g |
| 40% Pt on Vulcan XC-72 | P10A400 | 1g/5g |
| 50% Pt on Vulcan XC-72 | P10A500 | 1g/5g |
| 60% Pt on Vulcan XC-72 | P10A600 | 1g/5g |
| 80% Pt on Vulcan XC-72 | P10A800 | 1g/5g |
| Pt Black, High surface area: 40-50 m2/g, Low density: 0.6-0.9 g/ml | P10V010 | 1g/5g |
| 20% Pt on Durable Carbon | P10D200 | 1g/5g |
| 20% Pt on Vulcan XC-72R | P10B200 | 1g/5g |
| 40% Pt on Vulcan XC-72R | P10B400 | 1g/5g |
| 60% Pt on Vulcan XC-72R | P10B600 | 1g/5g |
| 40% Pt on high surface area Ketjenblack | P10E400 | 1g/5g |
| 50% Pt on high surface area Ketjenblack, | P10E500 | 1g/5g |
| 60% Pt on high surface area Ketjenblack | P10E600 | 1g/5g |
| 70% Pt on high surface area Ketjenblack | P10E700 | 1g/5g |
| 5% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A050 | 1g/5g |
| 10% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A100 | 1g/5g |
| 20% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A200 | 1g/5g |
| 30% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A300 | 1g/5g |
| 40% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A400 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72R | P12B600 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A600 | 1g/5g |
| 80% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A800 | 1g/5g |
| Pt-Ru Black (1:1 atomic ratio) | P12V010 | 1g/5g |
| Pt-Ru Black (2.5:1 atomic ratio) | P12V250 | 1g/5g |
| Pt-Ru-Ir Black (1:1:1 atomic ratio) | P124V010 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E600 | 1g/5g |
| 75% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E750 | 1g/5g |
| 20% Pt-Pd (1:3 atomic ratio) on Vulcan XC-72 | P13A203 | 1g/5g |
| 20% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A200 | 1g/5g |
| 20% Pt-Pd (3:1 atomic ratio) on Vulcan XC-72 | P13A230 | 1g/5g |
| 40% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A400 | 1g/5g |
| Pt-Pd Black (1:1 atomic ratio) | P13V010 | 1g/5g |
| Pt-Rh Black (1:1 atomic ratio) | P15V010 | 1g/5g |
| 20% Pt-Ir (1:3 atomic ratio) on Vulcan XC-72 | P14A203 | 1g/5g |
| 20% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A200 | 1g/5g |
| 20% Pt-Ir (3:1 atomic ratio) on Vulcan XC-72 | P14A230 | 1g/5g |
| 40% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A400 | 1g/5g |
| Pt-Ir Black (1:1 atomic ratio) | P14V010 | 1g/5g |
| 20% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA230 | 1g/5g |
| 40% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA430 | 1g/5g |
| 20% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA200 | 1g/5g |
| 40% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA400 | 1g/5g |
| 40% Pt-Fe (3:1 atomic ratio) on Vulcan XC-72 | P1BA430 | 1g/5g |
| 20% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA200 | 1g/5g |
| 20% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA230 | 1g/5g |
| 40% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA400 | 1g/5g |
| 40% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA430 | 1g/5g |
| 60% Pt-Co (3:1 atomic ratio) on Ketjenblack | P1CE630 | 1g/5g |
| 20% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA200 | 1g/5g |
| 20% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA230 | 1g/5g |
| 40% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA400 | 1g/5g |
| 40% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA430 | 1g/5g |
| 60% Pt-Ni (3:1 atomic ratio) on Ketjenblack | P1DE630 | 1g/5g |
| 20% Pt-Cu (1:1 atomic ratio) on Vulcan XC-72 | P1EA200 | 1g/5g |
| 20% Pt-Cu (3:1 atomic ratio) on Vulcan XC-72 | P1EA230 | 1g/5g |
| 20% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA230 | 1g/5g |
| 40% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA430 | 1g/5g |
| 20% Pd-Ir (1:3 atomic ratio) on Vulcan XC-72 | P34A203 | 1g/5g |
| 20% Pd-Ir (1:1 atomic ratio) on Vulcan XC-72 | P34A200 | 1g/5g |
| 20% Pd-Ir (3:1 atomic ratio) on Vulcan XC-72 | P34A230 | 1g/5g |
| 20% Pd-Rh (1:1 atomic ratio) on Vulcan XC-72 | P35A200 | 1g/5g |
| 20% Pd-Rh (3:1 atomic ratio) on Vulcan XC-72 | P35A230 | 1g/5g |
| 20% Pd-Ni (1:1 atomic ratio) on Vulcan XC-72 | P3DA200 | 1g/5g |
| 40% Pd-Au (1:1 atomic ratio) on Ketjenblack | P13E400 | 1g/5g |
| 5% Pd on Vulcan XC-72 | P30A050 | 1g/5g |
| 10% Pd on Vulcan XC-72 | P30A100 | 1g/5g |
| 20% Pd on Vulcan XC-72 | P30A200 | 1g/5g |
| 40% Pd on Vulcan XC-72 | P30A400 | 1g/5g |
| 40% Pd on Ketjenblack | P30E400 | 1g/5g |
| 60% Pd on Vulcan XC-72 | P30A600 | 1g/5g |
| 80% Pd on Vulcan XC-72 | P30A800 | 1g/5g |
| Pd Black, High surface area 40~48 m2/g | P30V010 | 1g/5g |
| 20% Ru on Vulcan XC-72 | P20A200 | 1g/5g |
| 40% Ru on Vulcan XC-72, | P20A400 | 1g/5g |
| Ru Black, High surface area 38~48 m2/g | P20V010 | 1g/5g |
| RuO2 powder, Surface area 18-25 m2/g | P20V020 | 1g/5g |
| 5% Ir on Vulcan XC-72 | P40A050 | 1g/5g |
| 10% Ir on Vulcan XC-72 | P40A100 | 1g/5g |
| 20% Ir on Vulcan XC-72 | P40A200 | 1g/5g |
| 40% Ir on Vulcan XC-72 | P40A400 | 1g/5g |
| Ir Black, High Surface area, 55~65 m2/g, | P40V010 | 1g/5g |
| IrOx powder, conductive, SA:10-20 m2/g | P40V020 | 1g/5g |
| Ru-Ir Black (1:1 atomic ratio) | P24V010 | 1g/5g |
| 20% Rh on Vulcan XC-72 | P50A200 | 1g/5g |
| Rh Black, High surface area 40~50 m2/g | P50V010 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: 4-8 nm) | P60N200 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: ~25 nm) | P60A200 | 1g/5g |
| 30% Au on Vulcan XC-72 (Au particle size: 8 nm) | P60N300 | 1g/5g |
| 40% Au on Vulcan XC-72 (Au particle size: ~35 nm) | P60A400 | 1g/5g |
| 40% Au on Ketjenblack (Au particle size: 4 nm) | P60E400 | 1g/5g |
| 60% Au on Vulcan XC-72 (Au particle size: ~45 nm) | P60A600 | 1g/5g |
| 5% Fe on Vulcan XC-72 | T10A050 | 1g/5g |
| 10% Fe on Vulcan XC-72 | T10A100 | 1g/5g |
| 20% Fe on Vulcan XC-72 | T10A200 | 1g/5g |
| 1% Co on Vulcan XC-72 | T20A010 | 1g/5g |
| 5% Co on Vulcan XC-72 | T20A050 | 1g/5g |
| 10% Co on Vulcan XC-72 | T20A100 | 1g/5g |
| 20% Co on Vulcan XC-72 | T20A200 | 1g/5g |
| 1% Ni on Vulcan XC-72 | T30A010 | 1g/5g |
| 5% Ni on Vulcan XC-72 | T30A050 | 1g/5g |
| 10% Ni on Vulcan XC-72 | T30A100 | 1g/5g |
| 20% Ni on Vulcan XC-72 | T30A200 | 1g/5g |
| 40% Ni on Vulcan XC-72 | T30A400 | 1g/5g |
| 1% Cu on Vulcan XC-72 | T40A010 | 1g/5g |
| 5% Cu on Vulcan XC-72 | T40A050 | 1g/5g |
| 10% Cu on Vulcan XC-72 | T40A100 | 1g/5g |
| 20% Cu on Vulcan XC-72 | T40A200 | 1g/5g |
| 40% Cu on Vulcan XC-72 | T40A400 | 1g/5g |
| 60% Cu on Vulcan XC-72 | T40A600 | 1g/5g |
| 20% Ag on Vulcan XC-72 | P70A200 | 1g/5g |
| 40% Ag on Vulcan XC-72 | P70A400 | 1g/5g |
| 60% Ag on Vulcan XC-72 | P70A600 | 1g/5g |
| 80% Ag on Vulcan XC-72 | P70A800 | 1g/5g |
| Platinum (II) acetylacetonate, 5 g each | P10H110 | 5g |
| (1,5-Cyclooctadiene)dimethylplatinum(II), 1 g each | P10H120 | 1g |
| Dichloro(1,5-cyclooctadiene)platinum(II), 5 g each | P10H130 | 5g |
| Diphenyl(1,5-cyclooctadiene)platinum(II), 5 g each | P10H140 | 5g |
| Trimethylbenzylammoniumhexachloroplatinate (IV), 1 g each | P10H150 | 1g |
| Palladium(II) acetylacetonate, 5 g each | P30H110 | 5g |
| Dichloro(1,5-cyclooctadiene)palladium(II), 5 g each | P30H120 | 5g |
| Hermann's Catalyst, 5 g each | P30H130 | 5g |
| 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride, 1 g each | P30H140 | 1g |
| Bis(dibenzylideneacetone)palladium(0), 5 g each | P30H150 | 5g |
| Palladium(0) tetrakis(triphenylphosphine), 5 g each | P30H160 | 5g |
| Ruthenium(III) acetylacetonate, 5 g each | P20H110 | 5g |
| Dichloro(1,5-cyclooctadiene)ruthenium(II), polymer, 5 g each | P20H120 | 5g |
| Bis(cyclopentadienyl)ruthenium, 5 g each | P20H130 | 5g |
| Irridium(III) acetylacetonate, 5 g each | P40H110 | 5g |
| Chloro(1,5-cyclooctadiene)iridium(I) dimer, 5 g each | P40H120 | 5g |
| Rhodium(III) acetylacetonate, 5 g each | P50H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 1 g each | P50H120 | 1g |
| Chloro(triphenylphosphine)gold(I), 5 g each | newitem3 | 5g |
| Bromo(triphenylphosphine)gold(I), 5 g each | P60H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Doyledirhodium catalyst-Rh2(5R-MPPIM)4, 1 g | P50-001 | 1g |
| Doyledirhodium catalyst-Rh2(5S-MPPIM)4, 1 g | P50-003 | 1g |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Trevigen致力于为研究人员提供高品质的试剂和试剂盒,用于细胞程序性死亡、DNA损伤和修复的研究。在过去的十年里,对于凋亡的研究越来越多,然而直到最近才开始将凋亡与DNA损伤联系在一起,并给予极大的关注。Trevigen能够为这一新兴领域提供高水平的产品和支持。而基于Trevigen在肿瘤研究产品核心业务的自然延伸,Trevigen开发出了一系列用于研究肿瘤细胞功能和行为的产品,包括血管生成、细胞侵袭、浸润和肿瘤形成等产品和试剂盒。所有Trevigen品牌的产品均基于最高质量标准生产,并被给予最强有力的技术支持。
Trevigen, Inc. is an innovative biotechnology company focused on the development of products and technology for cancer research and genetic toxicology, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 “Technology Corridor” in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Trevigen"> Trevigen
MoBiTec公司位于德国Göttingen,成立于1987年,致力于为细胞和分子生物学领域提供创造性的工具产品。
MoBiTec公司产品涵盖two- & one-hybrid systems、a phagemid display system、convenient Lambda PS genomic libraries、kits for efficient expression and purification of recombinant proteins、cell transfection reagents and cell culture tools、immobilized and soluble enzymes, many products for genomics and proteomics research, numerous antibodies, cytokines, growth factors and recombinant proteins, superior fluorescence reagents and kits.
MoBiTec的主要产品包括:
(1)Vector Systems
Bacillus Expression Systems
Lactococcus Expression Systems
Yeast Expression Systems等
(2)Genomics
Nucleic Acid Purifcation and Isolation
CRISPR/Cas9 Genome Editing
Magnetic Beads DNA Tools等
(3)Proteomics
Gel Staining, Quantitation and
Western Blots
Magnetic Beads等
(4)Antibodies and Peptides
Antibody Database Search
Primary Antibodies
Secondary Antibodies等
(5)Fluorescence Technology
Fluorescent Dyes
Fluorometric Assays
Fluorescent Indicator Dyes等
(6)Cell Biology
Transfection
Electroporation
Cells and Cell Culture Media等
Glycobiology
Carbohydrates from Dextra
Glycoassays from Sumitomo等
(7)Interaction Screening
Two- and One Hybrid Systems
Phagemid Display
RNA/Protein Interaction and Protein/Protein Interaction等
(8)In Vitro Diagnostics and Assays
Cell Viability, Proliferation and Function
Infectious Serology
Disease Monitoring等
(9)Lab Supplies
Mobicols and Plastic Columns
Microscopy Accessories
Plastic Supply等
(10)Chemicals and Buffers
Additives
Media and Components
Western Blotting and ELISA等
(11)Customized Services
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="MoBiTec"> MoBiTec
艾美捷科技代理IHC World品牌。
IHC World公司的产品与服务包括:
(1)抗体:提供多种一抗和二抗,适用于不同靶标和物种。
(2)试剂盒:包括染色试剂盒、检测试剂盒等,简化实验流程。
(3)仪器与设备:提供染色机、切片机等实验室设备。
(4)耗材:如玻片、盖玻片、封片剂等。
(5)定制服务:根据客户需求提供定制抗体开发和优化服务。
IHC World公司的产品应用领域:
(1)癌症研究:用于肿瘤标志物检测和癌症分型。
(2)神经科学:研究神经系统疾病和神经标记物。
(3)传染病研究:检测病原体及其在组织中的分布。
(4)药物开发:评估药物对组织的影响。
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理IHC World品牌"> 艾美捷科技代理IHC World品牌

美国Neuro Probe公司专业提供用于趋化实验的耗材(Transwell),更好地服务于药筛和基础实验研究领域。着重开发研究细胞活性实验相关的耗材,从第一代用于趋化实验的Boyden Chamer(单孔小室)到48微孔板的趋化小室,再到今天的ChemTx System他们始终与科学实验的步伐保持一致,追求创新,不断地开发新产品以满足多样化的实验需求。
Neuro Probe was founded in the late 1960’s with an initial focus on the development and manufacture of chronic stereotactic equipment. In the early 1970’s, corporate growth and diversification lead to the development and production of chemotactic instruments, beginning with the modified Boyden chamber and then assorted blind well chambers. In 1980, the 48-well microchemotaxis chamber was developed, in collaboration with Dr. Edward Leonard and Dr. Werner Falk working at the National Institutes of Health. This chamber has become a standard in the field and has served as a basis for the development of many new products. Most recently introduced is the ChemoTx® system. Please visit the Products section of our website for more information on specific products.
Neuroprobe的主要产品包括:
ChemoTx®
Chemotaxis Chambers
Single Well Chambers
Filters
Replacement Gaskets
Chemotaxis Accessories
Protein Crystallography
Cell Settling Chambers
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

TiterMax®佐剂被用于增强免疫反应。TiterMax®佐剂有着跟弗氏佐剂相同的功效,但具有更安全、更易用的特点,是弗氏佐剂的理想代替产品。
TiterMax® adjuvants are used to produce cell mediated and humoral responses in research animals. TiterMax® adjuvants were developed to meet the specific needs of investigators for immunoadjuvants that are at least as effective as Freund's Complete Adjuvant, safer and easier to use. They are an attractive alternative to Freund's Complete Adjuvant for use by researchers in inducing antibody to diverse antigens. The key to the potency of TiterMax® adjuvants lies both in the immunostimulatory activity of their components and in the fact that they form a stable water-in-oil emulsion. TiterMax® adjuvants contain three essential ingredients: Proprietary block copolymers, squalene, a metabolizable oil, and a unique microparticulate stabilizer. Like Freund's Complete Adjuvant, TiterMax® adjuvants can be used with a wide variety of antigens because they can entrap any antigen in a water-in-oil emulsion. TiterMax® adjuvants aid in the antigens effective presentation to the immune system without the toxic effects of Freund's Complete Adjuvant.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="TiterMax"> TiterMax
AdipoGen Lifesciences 位于美国和瑞士,并在全球遍布分销网络。该公司主要专注于生产最新型的炎症反应、免疫应答和免疫代谢研究方面的产品。产品类型涵盖抗体、生物化学品、细胞系、酶联免疫吸附试验试剂盒、天然产物、蛋白质及其它生化试剂。
AdipoGen is a manufacturer of Products for Advanced Inflammation, Immune Response & Immunometabolic Research. Product include Antibodies, Assays, Biochemicals, Cell Lines, ELISA KITS, Natural Products, Proteins, Other Reagents, Cancer, Immunology, Inflammation, Metabolism, Services and so on.
主要研究方向
(1)炎症;
(2)免疫:天然免疫、自然杀伤性T细胞(NKT细胞)、T细胞生物学、感染;
(3)肿瘤研究:细胞死亡研究、药物抗性、生物标记物、血管新生;
(4)代谢:糖尿病、肥胖症、脂肪因子、动脉粥样硬化性心血管疾病、线粒体功能障碍。
具体产品类型:
Notch信号通道(Notch受体& Notch配体)、内脏脂肪素(Nampt/PBEF)、颗粒蛋白前体、脂联素(ACRP30)、视黄醇结合蛋白4(RBP4)、白介素/炎症研究(IL33/IL17A)、Vaspin、ANGPTLs家族、FGF家族、脂肪因子其他产品(抵抗素/网膜素……)
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="AdipoGen Lifesciences"> AdipoGen Lifesciences
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技特约代理Bio X Cell抗体产品。
Bio X Cell位于美国Lebanon, New Hampshire,专注于为生物医药领域制造从毫克到克级的高品质单克隆抗体。
Bio X Cell specializes in manufacturing high quality, bulk quantity (milligram to gram) monoclonal antibodies for biomedical research. All our products are manufactured in the United States in our Lebanon, New Hampshire facility. At Bio X Cell we strive to provide scientists with ultra-pure antibodies targeting both well-characterized and novel antigens in the large quantities required for in vivo preclinical studies. We aim to facilitate the advancement of scientific discovery and innovation by providing our products at outstanding prices and backing them up with exceptional customer and technical support.
Bio X Cell的主要抗体包括:
(1)按CELL TYPE分为
T Cells
B Cells
NK Cells
Neutrophils
Monocytes & Macrophages
Dendritic Cells
(2)按AREA OF RESEARCH分为
Immunology
Innate Immunity
Cancer Biology
Immune Checkpoint Proteins
Cytokines and Chemokines
Cytokine Receptors
Cell Migration & Adhesion
Apoptosis
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Bio X Cell抗体产品"> 艾美捷科技特约代理Bio X Cell抗体产品地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:15172469628
邮箱:sales@amyjet.com
0.3031